Swiss Companies Show Reluctance to Invest in US Market

Uncertainty is currently the only currency trading at high volume between Switzerland and the United States. Major Swiss corporations are slamming the brakes on US investment, adopting a rigid "wait and see" stance that defies President Donald Trump's aggressive invitation to invest. The threat of looming tariffs has created a climate of hesitation that is palpable across Swiss boardrooms.

Rahul Sahgal, director of the Swiss-US Chamber of Commerce, cuts straight to the heart of the issue: "Companies do not know whether there will be a recession in the US and whether the American market will remain attractive." This is not merely caution; it is a calculated freeze. While the US administration pushes for capital influx, Swiss executives are refusing to commit blindly to a market grappling with potential economic volatility. The fear of a recession outweighs the allure of tax incentives, leaving billions in potential investment capital sitting idle in Zurich and Geneva, waiting for the fog of trade war rhetoric to clear.

In a bold rejection of pressure to relocate, Swatch is doubling down on its Swiss heritage. The watchmaking titan has signaled it will remain fiercely loyal to domestic production, declaring that the "Swiss Made" label is essential for its customers. While new retail shops will open on American soil, the intricate manufacturing that defines the brand will not be exported to satisfy US trade demands.

This sentiment echoes through the industrial sector. Chemical powerhouse Clariant, lift manufacturer Schindler, and dental implant specialist Straumann—all of whom already possess US factories—have explicitly stated they have no plans to expand production facilities. They are holding the line. Unlike the rush to appease US regulators seen in other nations, these Swiss giants are standing their ground, refusing to overextend into a market where the rules of engagement could change overnight. The message is clear: Swiss quality cannot be coerced.

While the general mood is one of reluctance, a significant fracture has emerged within the pharmaceutical sector. Industry titans Roche and Novartis are bucking the national trend, aggressively announcing new investments in the US market. These behemoths are betting that the US healthcare demand will outlast any temporary trade turbulence. Their strategy is proactive, seizing market share while others hesitate.

However, this confidence is not universal. Sandoz is making no moves, and Lonza is merely observing the situation, paralyzed by the same uncertainty affecting the broader economy. Outside of big pharma, the list of bold investors is critically short. Only three other major players—industrial manufacturer Georg Fischer, engineering giant ABB, and dermatological specialist Galderma—have announced new financing. This stark contrast highlights a split in Swiss corporate strategy: the few who see opportunity in the chaos, and the many who see only risk.

For some Swiss giants, the tariff threat is a storm they are already built to weather. Food colossus Nestlé stands in a league of its own, producing a staggering 90% of the items it sells in the US locally. This massive local footprint acts as a formidable shield against trade barriers, rendering import tariffs largely irrelevant to their core US operations. Flavour specialist Givaudan is on the same wavelength, pursuing a strict local production strategy to serve the market from within.

Meanwhile, premium chocolatier Lindt & Sprüngli is expanding its US presence, though the company clarifies this is the result of a long-standing decision rather than a reaction to recent political shifts. Logistics leader Kühne+Nagel takes a more pragmatic, reactive approach, relying entirely on client demand to dictate its footprint. These companies demonstrate that the best defense against trade uncertainty isn't hesitation—it's having been deeply embedded in the American economy all along.